Daniel O’Day, Chairman and CEO of Gilead Sciences (GILD), has demonstrated a clear selling bias in his recent insider transactions, with no buys and 14 sales recorded since September 2025. His sales have been substantial, totaling over $78.1 million in aggregate value, far outweighing his $15.2 million in total buys across his entire trading history. Notably, O’Day executed two major disposals in early 2026: a $17.3 million sale on February 5 and a $15.6 million sale on January 23, both accompanied by derivative transactions marked as "M" (likely option exercises). Smaller but consistent sales occurred throughout late 2025 and early 2026, including a $1.37 million transaction on March 27, 2026, and multiple six-figure disposals in prior months. The pattern suggests ongoing monetization of his Gilead holdings, with sales occurring at regular intervals—often at month-end—and no offsetting purchases. While some transactions appear tied to derivative events (such as the $7.6 million "M" coded transactions), the overall trend reflects a reduction in exposure to GILD stock. O’Day’s activity is confined exclusively to Gilead, with no trades in other securities disclosed in the filings. The absence of recent buys and the frequency of sales indicate a sustained disposition strategy rather than accumulation.
AI-assisted summary